All In Biotech

Drug Trial Radar · NCT07795593

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy (MCPAIN)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

May 2031

Study completion Jul 2031

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research team will perform a comparative-effectiveness sequential, multiple assignment, randomized trial in painful diabetic neuropathy (PDN) patients for 8 total months, divided into two 4-month stages. 600 participants 18+ with PDN will be enrolled in this study. The main goal is to compare the utility of three modalities (oral, topical, and behavioral) for initial PDN treatment, and to compare the utility of switching modalities versus continuing with the same modality for non-responders. Pain and discontinuation will be assessed weekly, whereas other outcomes will be assessed monthly for 8 months.

Conditions

  • Painful Diabetic Neuropathy (PDN)
  • Diabetic Nephropathies

Interventions

  • Cognitive Behavioral Therapy (CBT)Device

    Participants will work with study team to begin web-based, self-guided CBT (non-significant risk device) or traditional (one on one) CBT with a therapist (behavioral, not a device).

  • Oral MedicationDrug

    Participants will work with their physician to select an oral medication from a list commonly used to treat PDN. Patients will follow standard of care dosing and tapering of the assigned drug. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's): Duloxetine, Venlafaxine, Desvenlafaxine Tricyclic Antidepressants (TCAs): Amitriptyline, Nortriptyline Gabapentinoids: Gabapentin, Pregabalin Sodium Channel Blockers: Oxcarbazepine, Lamotrigine, Lacosamide

  • Topical MedicationDrug

    Participants will work with their physician to select a topical medication from a list commonly used to treat PDN. 0.075% capsaicin cream (4 times daily) 4-5% lidocaine patches (1-4 patches every 24 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-centered utility function as a measure for efficacy and tolerabilityTime frame: Up to 8 months.

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California

  • University of Florida-Jacksonville

    Jacksonville, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Tulane University

    New Orleans, Louisiana

  • Johns Hopskins University

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Allina Health-Neurosciences Research

    Minneapolis, Minnesota

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Missouri

    Columbia, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Columbia University

    New York, New York

  • Weill Cornell Medicine

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Duke University

    Durham, North Carolina

  • Oregon Health & Science University

    Portland, Oregon

  • University of Pittsburgh

    Titusville, Pennsylvania

  • Meharry Medical College

    Nashville, Tennessee

  • University of Vanderbilt

    Nashville, Tennessee

  • DHR Health Institute for Research and Development

    Edinburg, Texas

  • BaylorScott & White University Medical Center

    McKinney, Texas

  • Essentia Health

    Spooner, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.